SCYNEXIS (SCYX) Stock: Buy, Sell, or Hold?
SCYX - SCYNEXIS, Inc.
$3.79
-0.02 (-0.66%)
▼
5d:
+3.13%
30d:
-14.94%
90d:
+6.02%
BUY
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 04, 2026
10d
Get Alerted When SCYX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SCYX shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: SCYX shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: SCYX is currently trading at $3.79, which is considered oversold relative to its 30-day fair value range of $3.89 to $4.82. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.6) compared to its historical average (1.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SCYX is showing sideways momentum. Immediate support is located at $3.54, while resistance sits at $4.15.
Market Sentiment: SCYX scores 69/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $36.33 (+859.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SCYX is showing sideways momentum. Immediate support is located at $3.54, while resistance sits at $4.15.
Market Sentiment: SCYX scores 69/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $36.33 (+859.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.89 -
$4.82
Company Quality Score
60/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (69/100)
- BULLISH: Trading 859.9% below Wall St target ($36.33)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- BULLISH: Bottoming setup score 69/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$3.89 -
$4.82
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.54
Resistance Level
$4.15
Current Trend
Sideways
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.63
Wall Street Target
$36.33
(+859.9%)
Revenue Growth (YoY)
-82.8%
Profit Margin
-53.3%
PE vs Historical
-1.6 vs 1.5
CHEAP
Share & Embed Analysis
Last updated: October 24, 2026 7:22 AM ET
Data refreshes hourly during market hours. Next update: 8:22 AM
Data refreshes hourly during market hours. Next update: 8:22 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SCYX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 56 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 47 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 38 SELL |
|
AMLX
Amylyx Pharmaceuticals I… |
STRONG BUY
12 analysts |
$43 | 54 HOLD |
